Rapport Therapeutics, Inc. (RAPP)
Nasdaq: RAPP · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2024
Who owns Rapport Therapeutics, Inc.
As filed with the SECHolders of 5% or more
4
Third Rock Ventures V, L.P. holds 13.1% of Common Stock, $0.001 par value per share, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
20
report now, of 23 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Third Rock Ventures V, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value per share · 19.5% in Feb 13, 2025
Capital International Investors
SCHEDULE 13G/A · filed Aug 12, 2026 · Common Stock
Cormorant Asset Management, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value per share · 6.19% in May 15, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Jan 21, 2026 · Common Stock
Johnson & Johnson
SCHEDULE 13G/A · filed Oct 22, 2025 · Common Stock, $0.001 par value · reported falling below 5%
Dr. James I. Healy ("Healy")
SCHEDULE 13D/A · filed Sep 18, 2025 · Common Stock, $0.001 par value · reported falling below 5%
What RAPP reports owning in othersstakes of 5% or more, and other ties
Rapport Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
72sales
11purchases
69sales on a scheduled plan
6people selling
$47.2Msold, in dollars
$22.0Mbought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window13 of 30 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Third Rock Ventures Vi, L.P. | director | 3 | $28.3M | 3 | 0 | $0 |
| Third Rock Ventures V, L.P. | director | 2 | $6.1M | 2 | 0 | $0 |
| Ceesay Abraham | Chief Executive Officer | 36 | $6.0M | 36 | 0 | $0 |
| Yeleswaram Krishnaswamy | Chief Development Officer | 11 | $4.5M | 10 | 0 | $0 |
| Gault Cheryl | Chief Operating Officer | 10 | $1.2M | 9 | 0 | $0 |
| Bredt David | Chief Scientific Officer | 10 | $1.1M | 9 | 0 | $0 |
| Healy James | director | 0 | $0 | 0 | 4 | $20.4M |
| Maraganore John | director | 0 | $0 | 0 | 2 | $200,000 |
| Ignelzi Troy A. | Chief Financial Officer | 0 | $0 | 0 | 1 | $100,000 |
| Sanchez Ramiro | director | 0 | $0 | 0 | 1 | $100,000 |
| Paul Steven M | director | 0 | $0 | 0 | 1 | $1.0M |
| Silva Paul M | director | 0 | $0 | 0 | 1 | $100,000 |
| Young Wendy B. | director | 0 | $0 | 0 | 1 | $100,000 |